University Hospitals Birmingham NHS Foundation Trust 

Commercial Capabilities

SPECIALIST SERVICES

• Medicine - Excellence in vascular, bariatric, pathology and infectious diseases

• Expertise in HIV/AIDS

• Paediatrics - Teenage and Young Adults Cancer

• Duchenne Muscular Dystrophy Hub site

• Neonatal Intensive care

• Midwifery 

• Surgery - Largest solid organ transplantation programme in Europe

• Thoracic surgery 

• Bone marrow transplants

• Trauma - Major Trauma Centre 

• Royal Centre for Defence Medicine (RCDM)

• Regional Centres -trauma, burns, plastics, neuroscience, dermatology, cancer centre

• Birmingham Regional Severe Asthma Service

• Regional interstitial and occupational lung disease service

• West Midlands Adult Cystic Fibrosis Centre

• Regional IMD/ Endocrine

• Regional centre for Infectious Diseases & Tropical Medicine

• WHO status for Immunology and Allergy service 

• Microbiology 

• Capabilities to deliver complex treatments including CAR-T, Advanced Therapies, Cell therapy, Gene Therapy (including GMO)

• Comprehensive Care Haemophilia Centre

SPECIALIST FACILITIES

• Dedicated research pharmacies at QE and Heartlands Hospital

• Dedicated research labs at QE, Heartlands Hospital, Good Hope Hospital and Solihull Hospital

• Dedicated research facilities at Heartlands, QE and Solihull Hospital

• Medical Innovation Development and Research Unit (MIDRU); dedicated research facilities 

• Clinical Research Facility; offering 24/7 research facilities to deliver complex early phase experimental research.  

• Centre for Rare Diseases; offering patients a single visit facility bringing together multidisciplinary teams 

• Inflammation Research Facility (QE)

• Netherwood House Research Facility (Solihull)

CHIEF INVESTIGATOR/PRINCIPAL  INVESTIGATOR EXPERTISE

• Early phase vaccination experience

• Expertise in Trauma research

• PI capabilities in every disease area

• UHB has dedicated research delivery teams within most disease areas, totalling over 240WTE research nurses, coordinators and other research delivery roles

AREAS KEEN TO GROW

• HIV 

• Blood Borne Viruses

• Infectious Diseases

• Audiology & Otology

• REACT (former NIHR SRMRC) - 24/7 Acute Care

• Surgery

• Upper GI

• Dermatology

• Ophthalmology

• Elective Surgery

• Cardiology

• LIPIDS

• Paediatrics

• Obs & Gynae 

OTHER KEY INFORMATION 

• UHB works to the HRA Assess, Arrange and Confirm process.  We aim to complete Assess within 30 working days and Arrange through to Confirm within a further 40 working days

• UHB has a streamlined study setup process aligned to national processes. Between January and May 2023 the median setup time for commercial studies is 58 working days. Please contact the Commercial Research Manager (amy.smith@uhb.nhs.uk) for more information. 

• The dedicated Commercial Research Manager meets regularly with key sponsors to monitor and support, facilitating timely engagement

UHB hosts the following NIHR research infrastructure:

• NIHR Applied Research Collaboration (West Midlands)

• NIHR Biomedical Resource Centre (Birmingham)

• NIHR Clinical Research Facility (Birmingham)

• NIHR Trauma Management MedTech Co-operative (Birmingham)

And the following other research infrastructure:

• Academic Health Sciences Network (West Midlands)

• MD-TEC (Medical Devices Testing and Evaluation Centre)

• MidTECH

• West Midlands Familial Hypercholesterolaemia Screening Service

• INSIGHT (Health Data Research Hub for Eye Health)

• PIONEER (Health Data Research Hub for Acute Care)

• PATHWAY (Research Data Hub)

• Central and South Genomic Medicine Service Alliance 

• UHB is equipped to deliver most trials including First in Human/Phase 1, with our dedicated research infrastructure which spans our sites.  We can work with sponsors to agree appropriate delivery of trials across our hospital sites, ensuring all patients can access trials

RECRUITMENT/SET UP ACHIEVEMENTS 

• CPMS ID 52280 BioNTECH ;  a nationally important study, UHB was able to open first in the country

• CPMS ID 54568 HIV Study: UHB opened as the first UK site despite tight timelines  

• CPMS ID 39639 Lung Cancer Study: randomised the first UK patient since 2019

• CPMS ID 45768 Surgical Heart Transplant study: UHB  is the CI site and has gone on to transplant the first donor heart using the perfusion device.  

• CPMS ID 51451  Cancer study – recruited the first two UK patients

Research 

Team